COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth

Experience with very mild #COVID19 disease courses in two severe eosinophilic asthmatics with complete eosinophil depletion due to benralizumab treatment counters the recent theories that eosinophilia is protective in COVID-19 infections https://bit.ly/3cnEFvg

Detalles Bibliográficos
Autores principales: Renner, Andreas, Marth, Katharina, Patocka, Karin, Idzko, Marco, Pohl, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569753/
https://www.ncbi.nlm.nih.gov/pubmed/33257916
http://dx.doi.org/10.1183/23120541.00457-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569753/
https://www.ncbi.nlm.nih.gov/pubmed/33257916
http://dx.doi.org/10.1183/23120541.00457-2020

Ejemplares similares